Johnny Mahlangu

12.8k citations

191 papers · 7.2k indexed · 5 hit papers · h-index 35

Hematology top 0.05%
Genetics top 0.5%
Molecular Biology top 10%
Oncology top 10%
Surgery top 10%

Co-authors: Alok Srivastava Adolfo Llinás Johannes Oldenburg Guy Young Elena Santagostino Midori Shima Jerzy Windyga Rebecca Kruse‐Jarres
Topics: Hemophilia Treatment and Research (158 papers)Platelet Disorders and Treatments (61 papers)Blood Coagulation and Thrombosis Mechanisms (57 papers)
Cited by: Hematology Genetics Oncology
Journals: New England Journal of Medicine The LancetSHILAP Revista de lepidopterología
Partner nations: South Africa United States United Kingdom

In The Last Decade

Johnny Mahlangu

173 papers receiving 7.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for the management of hemophilia

2012 1.4k citations Alok Srivastava, Johnny Mahlangu et al. Haemophilia profile →
WFH Guidelines for the Management of Hemophilia, 3rd edition

2020 1.1k citations Alok Srivastava, Elena Santagostino et al. Haemophilia profile →
Emicizumab Prophylaxis in Hemophilia A with Inhibitors

2017 759 citations Johannes Oldenburg, Johnny Mahlangu et al. profile →
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

2018 503 citations Johnny Mahlangu, Johannes Oldenburg et al. profile →
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

2019 263 citations Guy Young, Tiffany Chang et al. Blood profile →

Peers

Countries citing papers authored by Johnny Mahlangu

Since Specialization

Citations

This map shows the geographic impact of Johnny Mahlangu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johnny Mahlangu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johnny Mahlangu more than expected).

Fields of papers citing papers by Johnny Mahlangu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johnny Mahlangu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johnny Mahlangu. The network helps show where Johnny Mahlangu may publish in the future.

Co-authorship network of co-authors of Johnny Mahlangu

This figure shows the co-authorship network connecting the top 25 collaborators of Johnny Mahlangu. A scholar is included among the top collaborators of Johnny Mahlangu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johnny Mahlangu. Johnny Mahlangu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A 2025 ·Haemophilia ·Johnny Mahlangu,Maria Elisa Mancuso,Kathelijn Fischer,Claudia Djambas Khayat,Manuela Carvalho,Faraizah Abdul Karim,Shawn M. Jobe,(unknown),(unknown),(unknown),Brahm Goldstein,Wilfried Seifert,(unknown),Christoph Königs	0
2	Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial 2025 ·Blood ·Davide Matino,Andrew Palladino,Carrie Turich Taylor,Eunhee Hwang,Sangeeta Raje,Satyaprakash Nayak,(unknown),Suchitra S. Acharya,Johnny Mahlangu,Víctor Jiménez‐Yuste,(unknown),(unknown),Chi Kong Li,Murtadha Al‐Khabori,Yasser Wali,(unknown),Young Shil Park,Bülent Zülfikar,John G. Teeter	3
3	Pociredir, a novel oral once-daily fetal hemoglobin inducer: Results from the Phase 1b pioneer study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness 2025 ·Blood ·(unknown),Johnny Mahlangu,Michael J. Birrer,M. Patrick Stagg,(unknown),(unknown),Caterina P. Minniti,Thomas Winkler,(unknown),Modupe Idowu	0
4	The genetic landscape of acute myeloid leukaemia in the South African public sector 2024 ·SHILAP Revista de lepidopterología ·(unknown),Pascale Willem,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Zivanai C. Chapanduka,(unknown),(unknown),Johnny Mahlangu,(unknown),Jessica Opie,J Potgieter,(unknown)	0
5	The translational gap for gene therapies in low- and middle-income countries 2024 ·Science Translational Medicine ·Kevin Doxzen,Jennifer E. Adair,Yris Maria Fonseca-Bazzo,(unknown),Kenneth Cornetta,(unknown),Renato Cunha,Suradej Hongeng,(unknown),(unknown),Lakshmanan Krishnamurti,Johnny Mahlangu,Julie Makani,Vikram Mathews,Margareth C. Ozelo,Savita Rangarajan,Janine Scholefield,(unknown),Joseph M. McCune	20
6	Trials in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase 1b CROSSWALK-a and Phase 2a CROSSWALK-c Trials - Crovalimab for the Treatment and Prevention of Vaso-Occlusive Episodes in Sickle Cell Disease 2023 ·Blood ·(unknown),Bülent Antmen,(unknown),Satheesh Chonat,Lucia De Franceschi,Perla Eleftheriou,Adlette Inati,Johnny Mahlangu,Erfan Nur,(unknown),(unknown),(unknown),Allison W. Hsia,(unknown),(unknown),(unknown),Pablo Bartolucci	0
7	Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis 2023 ·Hämostaseologie ·Johnny Mahlangu,(unknown),Susan Shapiro,(unknown),Margareth C. Ozelo,Gili Kenet,Flora Peyvandi,(unknown),(unknown),Amy L. Dunn,Jody M. Mason,Doris Quon,Andrew D. Leavitt,Johannes Oldenburg,Hérvè Chambost,Mark T. Reding,(unknown),(unknown),Tara M. Robinson,S. W. PIPE	1
8	Underdiagnosis of iron deficiency anaemia in HIV-infected individuals: a pilot study using soluble transferrin receptors and intensive bone marrow iron stores to improve the diagnosis 2022 ·Journal of Clinical Pathology ·(unknown),Ebrahim Variava,(unknown),(unknown),Khuthadzo Hlongwane,(unknown),(unknown),(unknown),Tracy Snyman,Neil Martinson,Johnny Mahlangu	2
9	Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study 2021 ·Journal of Clinical Medicine ·Gili Kenet,Yeu‐Chin Chen,Gillian Lowe,Charles Percy,Huyen Tran,Annette von Drygalski,Marc Trossaërt,Mark T. Reding,Johannes Oldenburg,María Eva Mingot‐Castellano,Young Shil Park,Flora Peyvandi,Margareth C. Ozelo,Johnny Mahlangu,Jennifer Quinn,(unknown),(unknown),Benjamin Kim	16
10	Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B 2021 ·Haemophilia ·Johnny Mahlangu,Howard Levy,Martin Lee,(unknown)	11
11	The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies 2021 ·Haemophilia ·Mark W. Skinner,Claude Négrier,Ido Paz‐Priel,Sammy Chebon,Víctor Jiménez‐Yuste,Michael U. Callaghan,Michaela Lehle,Markus Niggli,Johnny Mahlangu,Amy D. Shapiro,Midori Shima,Avrita Campinha‐Bacote,Gallia G. Levy,Johannes Oldenburg,Sylvia von Mackensen,Steven W. Pipe	34
12	A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH 2021 ·Journal of Thrombosis and Haemostasis ·Karin P. M. van Galen,Roseline d’Oiron,Paula James,Rezan A. Kadir,Peter A. Kouides,Roshni Kulkarni,Johnny Mahlangu,Maha Othman,Flora Peyvandi,(unknown),Rochelle Winikoff,Robert F. Sidonio	91
13	Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study 2020 ·Haemophilia ·Maria Elisa Mancuso,Johnny Mahlangu,Robert F. Sidonio,Peter C. Trask,Marianne Uguen,Tiffany Chang,Midori Shima,Guy Young,Johannes Oldenburg,Sylvia von Mackensen	18
14	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies 2020 ·Blood ·Michael U. Callaghan,Claude Négrier,Ido Paz‐Priel,Tiffany Chang,Sammy Chebon,Michaela Lehle,Johnny Mahlangu,Guy Young,Rebecca Kruse‐Jarres,Maria Elisa Mancuso,Markus Niggli,Monet Howard,Nives Selak Bienz,Midori Shima,Víctor Jiménez‐Yuste,Christophe Schmitt,Elina Asikanius,Gallia G. Levy,Steven W. Pipe,Johannes Oldenburg	170
15	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH 2020 ·Journal of Thrombosis and Haemostasis ·Barbara A. Konkle,(unknown),Donna Coffin,(unknown),(unknown),Lindsey A. George,Alfonso Iorio,Brian O’Mahony,Steven W. Pipe,Mark W. Skinner,(unknown),Flora Peyvandi,Johnny Mahlangu	35
16	Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein 2017 ·Haemophilia ·Johannes Oldenburg,Roshni Kulkarni,Alok Srivastava,Johnny Mahlangu,Victor S. Blanchette,Elisa Tsao,Bent Winding,Jennifer Dumont,Nisha Jain	38
17	Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting 2017 ·Blood ·Johannes Oldenburg,Midori Shima,Rebecca Kruse‐Jarres,Elena Santagostino,Johnny Mahlangu,Nives Selak Bienz,Sammy Chebon,Elina Asikanius,Gallia G. Levy	2
18	TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity 2016 ·Haemophilia ·Johnny Mahlangu,P. de Paz,(unknown),Fred Aswad,Jens Schroeder	21
19	Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study 2013 ·Journal of Thrombosis and Haemostasis ·Jerry S. Powell,Shashikant Apte,Hérvè Chambost,(unknown),Shaun P. Jackson,Neil C. Josephson,Johnny Mahlangu,(unknown),Kathelijne Peerlinck,Geoffrey Allen	4
20	Point-of-care estimation of haemoglobin concentration in neonates and infants 2012 ·South African Journal of Child Health ·Elise Schapkaitz,Johnny Mahlangu,(unknown)	4

About Johnny Mahlangu

Johnny Mahlangu is a scholar working on Hematology, Genetics and Hepatology, having authored 191 papers that have together received 7.2k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (158 papers), Platelet Disorders and Treatments (61 papers) and Blood Coagulation and Thrombosis Mechanisms (57 papers). The work is most often cited by research in Hematology (6.6k citations), Genetics (1.7k citations) and Oncology (442 citations). Johnny Mahlangu has collaborated with scholars based in South Africa, United States and United Kingdom. Frequent co-authors include Alok Srivastava, Adolfo Llinás, Johannes Oldenburg, Guy Young, Elena Santagostino, Midori Shima, Jerzy Windyga, Rebecca Kruse‐Jarres, Gallia G. Levy and Nigel S. Key. Their work appears in journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact